Birth Injury Marketing
Economics

Cost per lead can fall while cost per signed case rises

By Kevin Schwaner, Founder; Chief Marketing OfficerUpdated

Cheaper inquiries can raise your cost per signed case. Here is the arithmetic, and the point at which it flips. Optimising toward cheaper inquiries shifts the mix toward matters less likely to survive screening, so cost per lead falls, the share passing screening falls with it, and screening cost per signed case rises faster than media cost per inquiry falls. Both movements are real. Only cost per signed case tells you whether the marketing paid for itself.

The mechanism, step by step

How cheaper leads produce more expensive cases. A six-step causal chain in which every reported metric improves while the outcome deteriorates. 1 · The campaign is optimised toward form fills, the only conversion the platform sees 2 · The bidding system finds cheaper form fills, which are systematically less qualified 3 · Cost per inquiry fallsreported as a win 4 · Screening pass rate fallsnot reported at all 5 · More inquiries are screened per signed case, and each one costs money 6 · Screening cost per signed case rises faster than media cost per inquiry falls Cost per signed case rises. The report is a page of green.
Figure 1: steps 3 and 4 happen simultaneously and only one of them is instrumented. That asymmetry is the whole problem, and it is a measurement failure before it is a media failure.

The arithmetic that produces the divergence

Total acquisition cost has four components, and most reporting shows one. Media spend, agency or in-house cost, the cost of obtaining records on every screened inquiry, and the cost of reviewing them. The last two scale with the number of inquiries screened, not with the number of cases signed, which is precisely why they invert the arithmetic when inquiry quality falls.

The four cost components, and which reporting shows them.
ComponentScales withUsually reported?
Media spendInquiriesYes
Agency or in-house costFixedSometimes
Cost to obtain recordsScreened inquiriesRarely
Cost to review recordsScreened inquiriesAlmost never, and it is frequently the largest

Put your own numbers through the model; it shows every step and you can reconstruct it on paper.

The four-question diagnostic

Run this on two consecutive quarters. The pattern in the right column is the failure mode.
QuestionHealthy patternThe failure pattern
Is cost per inquiry falling?Either direction is fine on its ownFalling
Is the share of inquiries passing screening falling?Stable or risingFalling at the same time
Is screening as a share of total acquisition cost rising?StableRising
Are signed cases rising?RisingFlat or falling

All four together is diagnostic. Any one alone is not.

The fix

Import signed-case outcomes into the ad platform as offline conversions, and bid to those instead of to form fills. Until that integration exists, automated bidding is optimising toward the cheapest inquiries available to it, and it will keep doing so with great efficiency. Everything else (better creative, tighter targeting, faster intake) helps, and none of it addresses the objective function.

The full argument is in the paid media manual, and the instrumentation is part 3 of the acquisition playbook.

Where acquisition cost actually sits, illustratively. The four components of total acquisition cost, showing that the two least-reported components can dominate. Media spend 34% % of total, always reportedCost to review records 31% %, almost never reportedAgency or in-house cost 22% %, sometimes reportedCost to obtain records 13% %, rarely reported
Figure 2: an illustrative split, not a benchmark. The shape is the point: the two components most reporting omits can together exceed the one it always shows, and they scale with inquiries screened rather than with cases signed. Put your own figures through the model to get your split.

The one question to ask any agency. "What is our cost per signed case, computed from our case management system rather than from the ad platform?" If the answer is a cost per lead, they have told you what they measure, and so has the bidding algorithm they are running.

Clinical measures and legal measures are never joined on this site. Adverse-event rates describe medicine; litigation describes a legal process. Where both appear together it is to describe a market, not to suggest that one predicts the other.

Sources

  1. U.S. Census Bureau: County Population Totals and Components of Change, 2024: births by county, 2021–2024
  2. CMS Care Compare: Maternal Health · Hospital: PC-02, PC-07a, PC-07b, SM-7; 2024 reporting period

Cite this analysis

Free to reproduce with attribution, including commercially. Charts may be embedded as published.

Birth Injury Marketing. “Cost per lead can fall while cost per signed case rises.” 25 August 2026. https://birthinjurymarketing.com/insights/cost-per-lead-is-the-wrong-metric-for-birth-injury/

Journalists and researchers: the underlying data is already published as CSV at /data/, free and without conditions, no form. Need a different cut, by state, county, hospital or year? Ask, and I will also tell you what the data cannot support.

More

Data · analysis

Where births and legal capacity are furthest apart

Joining county births to Offices-of-Lawyers establishments produces a market map nobody has assembled, and a measure much weaker than it looks.

Operations

Why more spend stops producing more birth injury cases

Signed case volume is limited by how many inquiries a firm can competently review, not by how many it receives. Above that ceiling, additional spend buys a queue.

All articles → · The data behind them → · The publications →

Authorship & review

Author
Kevin Schwaner, Founder; Chief Marketing Officer. Credentials.
Last reviewed
Corrections
Found an error? Tell me and it goes in the dated corrections log, whether or not it flatters me.